COVID-19：考虑使用白细胞介素 6 受体拮抗剂治疗 SARS-CoV-2 感染患者的细胞因子风暴综合征。
COVID-19: Consider IL-6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients.
机构信息
Department of Biotechnology, School of Life Science and Biotechnology, Adamas University, Kolkata, West Bengal, India.
Institute for Skeletal Aging & Orthopedic Surgery, Hallym University-Chuncheon Sacred Heart Hospital, Chuncheon-si, Gangwon-do, Korea.
出版信息
J Med Virol. 2020 Nov;92(11):2260-2262. doi: 10.1002/jmv.26078. Epub 2020 Jun 19.
Abstract
COVID-19 leads to mortality of several patients and the cytokine storm is reportedly critical in the patients. To reduce the cytokine storm, we would like to propose the interleukin (IL) 6 receptor (IL-6R) antagonist therapy for the COVID-19 patients. Two humanized monoclonal antibodies are in clinical trial following IL-6R antagonist therapies namely tocilizumab and sarilumab. However, researchers and physicians should look for more IL-6R antagonists for the therapy of cytokine storm syndrome severe acute respiratory syndrome coronavirus 2 infected persons to enhance the therapeutic options for cytokine storm.
摘要
COVID-19 导致多名患者死亡，据报道细胞因子风暴在患者中至关重要。为了减少细胞因子风暴，我们希望为 COVID-19 患者提出白细胞介素（IL）6 受体（IL-6R）拮抗剂治疗方法。两种人源化单克隆抗体是在临床试验中紧随 IL-6R 拮抗剂疗法之后的，即托珠单抗和沙利鲁单抗。然而，研究人员和医生应该寻找更多的 IL-6R 拮抗剂来治疗细胞因子风暴综合征严重急性呼吸综合征冠状病毒 2 感染患者，以增强细胞因子风暴的治疗选择。
相似文献
1
COVID-19: Consider IL-6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients.
J Med Virol. 2020 Nov;92(11):2260-2262. doi: 10.1002/jmv.26078. Epub 2020 Jun 19.
2
Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19.
Arch Med Res. 2020 Aug;51(6):595-597. doi: 10.1016/j.arcmed.2020.05.009. Epub 2020 May 21.
3
Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
Rev Recent Clin Trials. 2021;16(2):138-145. doi: 10.2174/1574887115666200917110954.
4
The Role of Tocilizumab in Cytokine Storm and Improving Outcomes in COVID-19.
Recent Pat Antiinfect Drug Discov. 2020;15(2):104-112. doi: 10.2174/1574891X15666200922155712.
5
Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2.
Medicine (Baltimore). 2021 May 14;100(19):e25923. doi: 10.1097/MD.0000000000025923.
6
Tocilizumab for the Treatment of COVID-19-Induced Cytokine Storm and Acute Respiratory Distress Syndrome: A Case Series From a Rural Level 1 Trauma Center in Western Pennsylvania.
J Investig Med High Impact Case Rep. 2021 Jan-Dec;9:23247096211019557. doi: 10.1177/23247096211019557.
7
Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality.
Int J Antimicrob Agents. 2020 May;55(5):105954. doi: 10.1016/j.ijantimicag.2020.105954. Epub 2020 Mar 29.
8
Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence.
Int J Mol Sci. 2021 Mar 17;22(6):3059. doi: 10.3390/ijms22063059.
9
Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.
J Med Virol. 2020 Nov;92(11):2516-2522. doi: 10.1002/jmv.26038. Epub 2020 Jun 9.
10
Tocilizumab as a Treatment for 'Cytokine Storm Syndrome' in COVID-19: A Case Report.
Acta Med Indones. 2021 Apr;53(2):194-201.
引用本文的文献
1
A feedback loop between DNA damage, genomic instability, and cytoplasmic DNA sensing contributes to cytokine production in COVID-19.
Arch Virol. 2025 Aug 11;170(9):192. doi: 10.1007/s00705-025-06383-6.
2
Structure-Based Design of Small-Molecule Inhibitors of Human Interleukin-6.
Molecules. 2025 Jul 10;30(14):2919. doi: 10.3390/molecules30142919.
3
Effect of Anti-Interleukin-6 Agents on Psychopathology in a Sample of Patients with Post-COVID-19 Syndrome: An Observational Study.
Brain Sci. 2024 Jan 3;14(1):47. doi: 10.3390/brainsci14010047.
4
Methyl 2-[3-(4-hydroxyphenyl)prop-2-enoylamino]-3-phenylpropanoate Is a Potent Cell-Permeable Anti-Cytokine Compound To Inhibit Inflammatory Cytokines in Monocyte/Macrophage-Like Cells.
J Pharmacol Exp Ther. 2024 Jan 2;388(1):181-189. doi: 10.1124/jpet.123.001830.
5
Blood filtering system for COVID-19 management: novel modality of the cytokine storm therapeutics.
Front Immunol. 2023 Apr 21;14:1064459. doi: 10.3389/fimmu.2023.1064459. eCollection 2023.
6
Severe COVID-19: Drugs and Clinical Trials.
J Clin Med. 2023 Apr 16;12(8):2893. doi: 10.3390/jcm12082893.
7
Tocilizumab-coated solid lipid nanoparticles loaded with cannabidiol as a novel drug delivery strategy for treating COVID-19: A review.
Front Immunol. 2023 Mar 22;14:1147991. doi: 10.3389/fimmu.2023.1147991. eCollection 2023.
8
Using Real-Time PCR Fluorescence Reaction Values to Improve SARS-CoV-2 Virus Detection and Benefit Clinical Decision-Making.
Life (Basel). 2023 Mar 2;13(3):683. doi: 10.3390/life13030683.
9
Homozygous-Recessive Characteristics as a Biomarker of Predisposition for COVID-19.
Clin Nurs Res. 2023 Mar;32(3):589-600. doi: 10.1177/10547738221147754. Epub 2023 Jan 25.
10
COVID-19: A state of art on immunological responses, mutations, and treatment modalities in riposte.
J Infect Public Health. 2023 Feb;16(2):233-249. doi: 10.1016/j.jiph.2022.12.019. Epub 2022 Dec 29.
本文引用的文献
1
Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19.
Arch Med Res. 2020 Aug;51(6):595-597. doi: 10.1016/j.arcmed.2020.05.009. Epub 2020 May 21.
2
SnapShot: COVID-19.
Cell. 2020 May 14;181(4):954-954.e1. doi: 10.1016/j.cell.2020.04.013. Epub 2020 Apr 30.
3
Immunoregulation with mTOR inhibitors to prevent COVID-19 severity: A novel intervention strategy beyond vaccines and specific antiviral medicines.
J Med Virol. 2020 Sep;92(9):1495-1500. doi: 10.1002/jmv.26009. Epub 2020 May 22.
4
Preventing cytokine storm syndrome in COVID-19 using α-1 adrenergic receptor antagonists.
J Clin Invest. 2020 Jul 1;130(7):3345-3347. doi: 10.1172/JCI139642.
5
Effective treatment of severe COVID-19 patients with tocilizumab.
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975. doi: 10.1073/pnas.2005615117. Epub 2020 Apr 29.
6
SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options.
Eur Rev Med Pharmacol Sci. 2020 Apr;24(7):4016-4026. doi: 10.26355/eurrev_202004_20871.
7
Cytokine release syndrome in severe COVID-19.
Science. 2020 May 1;368(6490):473-474. doi: 10.1126/science.abb8925. Epub 2020 Apr 17.
8
The pathogenesis and treatment of the `Cytokine Storm' in COVID-19.
J Infect. 2020 Jun;80(6):607-613. doi: 10.1016/j.jinf.2020.03.037. Epub 2020 Apr 10.
9
Tocilizumab treatment in COVID-19: A single center experience.
J Med Virol. 2020 Jul;92(7):814-818. doi: 10.1002/jmv.25801. Epub 2020 Apr 15.
10
A panoramic review of IL-6: Structure, pathophysiological roles and inhibitors.
Bioorg Med Chem. 2020 Mar 1;28(5):115327. doi: 10.1016/j.bmc.2020.115327. Epub 2020 Jan 20.
Zotero 插件